{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:09:04Z","timestamp":1789823344162,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transmission-blocking vaccines (TBV) target the sexual-stages of the malaria parasite in the mosquito midgut and are widely considered to be an essential tool for malaria elimination. High-titer functional antibodies are required against target antigens to achieve effective transmission-blocking activity. We have fused Pfs25, the leading malaria TBV candidate antigen to IMX313, a molecular adjuvant and expressed it both in ChAd63 and MVA viral vectors and as a secreted protein-nanoparticle. Pfs25-IMX313 expressed from viral vectors or as a protein-nanoparticle is significantly more immunogenic and gives significantly better transmission-reducing activity than monomeric Pfs25. In addition, we demonstrate that the Pfs25-IMX313 protein-nanoparticle leads to a qualitatively improved antibody response in comparison to soluble Pfs25, as well as to significantly higher germinal centre (GC) responses. These results demonstrate that antigen multimerization using IMX313 is a very promising strategy to enhance antibody responses against Pfs25 and that Pfs25-IMX313 is a highly promising TBV candidate vaccine.<\/jats:p>","DOI":"10.1038\/srep18848","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T11:25:28Z","timestamp":1452252328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology"],"prefix":"10.1038","volume":"6","author":[{"given":"Yuanyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren B.","family":"Leneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoyo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Nikolaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona J.","family":"Brian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D. J.","family":"Dicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Fyfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Zakutansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"de Cassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole A.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergal","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"BFsrep18848_CR1","unstructured":"World-Health-Organisation. World Malaria Report 2014. World Health Organization, Geneva, Switzerland."},{"key":"BFsrep18848_CR2","doi-asserted-by":"crossref","unstructured":"Mo, A. X. Y. & Augustine, A. D. NIAID meeting report: Improving malaria vaccine strategies through the application of immunological principles. Vaccine32, 1132\u20131138 (2014).","DOI":"10.1016\/j.vaccine.2013.09.011"},{"key":"BFsrep18848_CR3","doi-asserted-by":"publisher","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"SCTP Rts","year":"2014","unstructured":"Rts, S. C. T. P. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS medicine 11, e1001685 (2014).","journal-title":"PLoS medicine"},{"key":"BFsrep18848_CR4","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(13)62238-2","volume":"382","author":"VS Moorthy","year":"2013","unstructured":"Moorthy, V. S., Newman, R. D. & Okwo-Bele, J.-M. Malaria vaccine technology roadmap. The Lancet 382, 1700\u20131701 (2013).","journal-title":"The Lancet"},{"key":"BFsrep18848_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/333074a0","volume":"333","author":"DC Kaslow","year":"1988","unstructured":"Kaslow, D. C. et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333, 74\u201376 (1988).","journal-title":"Nature"},{"key":"BFsrep18848_CR6","doi-asserted-by":"crossref","unstructured":"Sauerwein, R. W. & Bousema, T. Transmission blocking malaria vaccines: Assays and candidates in clinical development. Vaccine (in press) doi: 10.1016\/j.vaccine.2015.08.073.","DOI":"10.1016\/j.vaccine.2015.08.073"},{"key":"BFsrep18848_CR7","doi-asserted-by":"crossref","unstructured":"Nikolaeva, D., Draper, S. J. & Biswas, S. Toward the development of effective transmission-blocking vaccines for malaria. Expert review of vaccines, 1\u201328 (2015) May;14(5), 653\u201380. doi: 10.1586\/14760584.2015.993383.","DOI":"10.1586\/14760584.2015.993383"},{"key":"BFsrep18848_CR8","doi-asserted-by":"publisher","first-page":"e2636","DOI":"10.1371\/journal.pone.0002636","volume":"3","author":"Y Wu","year":"2008","unstructured":"Wu, Y. et al. Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51. PLoS ONE 3, e2636 (2008).","journal-title":"PLoS ONE"},{"key":"BFsrep18848_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/eji.201242687","volume":"43","author":"AC Tissot","year":"2013","unstructured":"Tissot, A. C. et al. A VLP-based vaccine against interleukin-1alpha protects mice from atherosclerosis. European journal of immunology 43, 716\u2013722 (2013).","journal-title":"European journal of immunology"},{"key":"BFsrep18848_CR10","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","volume":"31","author":"RL Shimp Jr","year":"2013","unstructured":"Shimp Jr, R. L. et al. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine 31, 2954\u20132962 (2013).","journal-title":"Vaccine"},{"key":"BFsrep18848_CR11","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1016\/j.vaccine.2007.02.073","volume":"25","author":"F Qian","year":"2007","unstructured":"Qian, F. et al. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: A strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine 25, 3923\u20133933 (2007).","journal-title":"Vaccine"},{"key":"BFsrep18848_CR12","doi-asserted-by":"publisher","first-page":"18243","DOI":"10.1073\/pnas.0608545103","volume":"103","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proceedings of the National Academy of Sciences of the United States of America 103, 18243\u201318248 (2006).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep18848_CR13","doi-asserted-by":"publisher","first-page":"e79538","DOI":"10.1371\/journal.pone.0079538","volume":"8","author":"RM Jones","year":"2013","unstructured":"Jones, R. M. et al. A Plant-Produced Pfs25 VLP Malaria Vaccine Candidate Induces Persistent Transmission Blocking Antibodies against Plasmodium falciparum in Immunized Mice. PLoS ONE 8, e79538 (2013).","journal-title":"PLoS ONE"},{"key":"BFsrep18848_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1073\/pnas.0609885104","volume":"104","author":"J Kubler-Kielb","year":"2007","unstructured":"Kubler-Kielb, J. et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proceedings of the National Academy of Sciences 104, 293\u2013298 (2007).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"BFsrep18848_CR15","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1128\/IAI.01369-07","volume":"76","author":"SA Ogun","year":"2008","unstructured":"Ogun, S. A., Dumon-Seignovert, L., Marchand, J. B., Holder, A. A. & Hill, F. The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. Infection and immunity 76, 3817\u20133823 (2008).","journal-title":"Infection and immunity"},{"key":"BFsrep18848_CR16","doi-asserted-by":"publisher","first-page":"e33555","DOI":"10.1371\/journal.pone.0033555","volume":"7","author":"AJ Spencer","year":"2012","unstructured":"Spencer, A. J. et al. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS One 7, e33555 (2012).","journal-title":"PLoS One"},{"key":"BFsrep18848_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1586\/erv.13.11","volume":"12","author":"SC de Cassan","year":"2013","unstructured":"de Cassan, S. C. & Draper, S. J. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert review of vaccines 12, 365\u2013378 (2013).","journal-title":"Expert review of vaccines"},{"key":"BFsrep18848_CR18","doi-asserted-by":"publisher","first-page":"e29428","DOI":"10.1371\/journal.pone.0029428","volume":"6","author":"AL Goodman","year":"2011","unstructured":"Goodman, A. L. et al. A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity. PloS one 6, e29428 (2011).","journal-title":"PloS one"},{"key":"BFsrep18848_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nbt0594-494","volume":"12","author":"DC Kaslow","year":"1994","unstructured":"Kaslow, D. C. & Shiloach, J. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Bio\/technology 12, 494\u2013499 (1994).","journal-title":"Bio\/technology"},{"key":"BFsrep18848_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nsmb1024","volume":"13","author":"AK Saxena","year":"2006","unstructured":"Saxena, A. K. et al. The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nature structural & molecular biology 13, 90\u201391 (2006).","journal-title":"Nature structural & molecular biology"},{"key":"BFsrep18848_CR21","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jmb.2012.12.017","volume":"425","author":"T Hofmeyer","year":"2013","unstructured":"Hofmeyer, T. et al. Arranged sevenfold: structural insights into the C-terminal oligomerization domain of human C4b-binding protein. Journal of molecular biology 425, 1302\u20131317 (2013).","journal-title":"Journal of molecular biology"},{"key":"BFsrep18848_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ncomms1615","volume":"2","author":"AD Douglas","year":"2011","unstructured":"Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature communications 2, 601 (2011).","journal-title":"Nature communications"},{"key":"BFsrep18848_CR23","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1128\/JVI.02568-07","volume":"82","author":"S Sridhar","year":"2008","unstructured":"Sridhar, S. et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. Journal of virology 82, 3822\u20133833 (2008).","journal-title":"Journal of virology"},{"key":"BFsrep18848_CR24","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1084\/jem.174.5.1203","volume":"174","author":"PJ Barr","year":"1991","unstructured":"Barr, P. J. et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. The Journal of experimental medicine 174, 1203\u20131208 (1991).","journal-title":"The Journal of experimental medicine"},{"key":"BFsrep18848_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.vaccine.2007.10.064","volume":"26","author":"K Miura","year":"2008","unstructured":"Miura, K. et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193\u2013200 (2008).","journal-title":"Vaccine"},{"key":"BFsrep18848_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nature reviews. Immunology 9, 287\u2013293 (2009).","journal-title":"Nature reviews. Immunology"},{"key":"BFsrep18848_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-3024.1994.tb00306.x","volume":"16","author":"AP Mountford","year":"1994","unstructured":"Mountford, A. P., Fisher, A. & Wilson, R. A. The profile of IgG1 and IgG2a antibody responses in mice exposed to Schistosoma mansoni. Parasite immunology 16, 521\u2013527 (1994).","journal-title":"Parasite immunology"},{"key":"BFsrep18848_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1128\/IAI.00740-09","volume":"78","author":"A Reyes-Sandoval","year":"2010","unstructured":"Reyes-Sandoval, A. et al. Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses. Infection and immunity 78, 145\u2013153 (2010).","journal-title":"Infection and immunity"},{"key":"BFsrep18848_CR29","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.4049\/jimmunol.1001760","volume":"185","author":"SJ Draper","year":"2010","unstructured":"Draper, S. J. et al. Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus and Protein-in-Adjuvant Vaccines. The Journal of Immunology 185, 7583\u20137595 (2010).","journal-title":"The Journal of Immunology"},{"key":"BFsrep18848_CR30","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.4049\/jimmunol.1101004","volume":"187","author":"SC de Cassan","year":"2011","unstructured":"de Cassan, S. C. et al. The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. The Journal of Immunology 187, 2602\u20132616 (2011).","journal-title":"The Journal of Immunology"},{"key":"BFsrep18848_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev.immunol.23.021704.115732","volume":"23","author":"LJ McHeyzer-Williams","year":"2005","unstructured":"McHeyzer-Williams, L. J. & McHeyzer-Williams, M. G. Antigen-specific memory B cell development. Annual Review of Immunology 23, 487\u2013513 (2005).","journal-title":"Annual Review of Immunology"},{"key":"BFsrep18848_CR32","doi-asserted-by":"publisher","first-page":"e44943","DOI":"10.1371\/journal.pone.0044943","volume":"7","author":"EK Forbes","year":"2012","unstructured":"Forbes, E. K. et al. T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. PLoS ONE 7, e44943 (2012).","journal-title":"PLoS ONE"},{"key":"BFsrep18848_CR33","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1016\/j.vaccine.2010.08.068","volume":"28","author":"AD Douglas","year":"2010","unstructured":"Douglas, A. D. et al. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28, 7167\u20137178 (2010).","journal-title":"Vaccine"},{"key":"BFsrep18848_CR34","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nbt0988-1065","volume":"6","author":"T Rutgers","year":"1988","unstructured":"Rutgers, T. et al. Hepatitis B Surface Antigen as Carrier Matrix for the Repetitive Epitope of the Circumsporozoite Protein of Plasmodium Falciparum. Nat Biotech 6, 1065\u20131070 (1988).","journal-title":"Nat Biotech"},{"key":"BFsrep18848_CR35","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1016\/j.vaccine.2013.10.041","volume":"31","author":"Y Vanloubbeeck","year":"2013","unstructured":"Vanloubbeeck, Y. et al. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine 31, 6216\u20136224 (2013).","journal-title":"Vaccine"},{"key":"BFsrep18848_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1073\/pnas.1112648109","volume":"109","author":"JJ Moon","year":"2012","unstructured":"Moon, J. J. et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proceedings of the National Academy of Sciences 109, 1080\u20131085 (2012).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"BFsrep18848_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nbt0594-494","volume":"12","author":"DC Kaslow","year":"1994","unstructured":"Kaslow, D. C. & Shiloach, J. Production, Purification and Immunogenicity of a Malaria Transmission-Blocking Vaccine Candidate: TBV25H Expressed in Yeast and Purified Using Nickel-NTA Agarose. Nat Biotech 12, 494\u2013499 (1994).","journal-title":"Nat Biotech"},{"key":"BFsrep18848_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nm.1850","volume":"14","author":"SJ Draper","year":"2008","unstructured":"Draper, S. J. et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14, 819\u2013821 (2008).","journal-title":"Nat Med"},{"key":"BFsrep18848_CR39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ncomms1615","volume":"2","author":"AD Douglas","year":"2011","unstructured":"Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature communications 2, 601 (2011).","journal-title":"Nature communications"},{"key":"BFsrep18848_CR40","unstructured":"Ausubel, F. M. Current Protocols in Molecular Biology. (Wiley, New York, NY; 1987)."},{"key":"BFsrep18848_CR41","doi-asserted-by":"publisher","first-page":"e57909","DOI":"10.1371\/journal.pone.0057909","volume":"8","author":"K Miura","year":"2013","unstructured":"Miura, K. et al. Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays. PLoS ONE 8, e57909 (2013).","journal-title":"PLoS ONE"},{"key":"BFsrep18848_CR42","doi-asserted-by":"crossref","unstructured":"Lambe, T. et al. Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. Sci. Rep. 3 doi: 10.1038\/srep01443 (2013).","DOI":"10.1038\/srep01443"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep18848","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18848.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18848.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:07:34Z","timestamp":1672873654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep18848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,10]]}},"alternative-id":["BFsrep18848"],"URL":"https:\/\/doi.org\/10.1038\/srep18848","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,8]]},"assertion":[{"value":"28 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SJD, AVSH and FH are named on patent applications relating to vaccines and immunization regimes. FH is an employee of Imaxio SA which owns rights to and is developing the IMX313 vaccine technology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18848"}}